贝伐单抗与雷珠单抗治疗年龄相关性黄斑变性全身安全性的Meta分析

发布时间：2018-06-15 06:11

  本文选题：年龄相关性黄斑变性 + 贝伐单抗　； 参考：《中国中医眼科杂志》2016年02期

【摘要】：目的评价贝伐单抗(Bevacizumab)与雷珠单抗(Ranibizumab)玻璃体腔内注射治疗年龄相关性黄斑变性的全身安全性。方法计算机检索Pubmed、EMbase、Cochrane Library、中国生物医学文献数据库(CBM)、中国知网(CNKI)、维普数据库(VIP)、万方数据库,查找有关Bevacizumab与Ranibizumab治疗年龄相关性黄斑变性的随机对照研究(RCT),同时追索纳入文献的参考文献。检索时限均为从建库至2013年12月1日。对纳入研究的质量进行严格评价和资料提取,对符合质量标准的RCT进行Meta分析。结果共纳入5个RCT,合计2382眼。各项研究中的全身安全性指标同质性较好,采用固定效应模型进行Meta分析。结果显示:Bevacizumab组与Ranibizumab组相比,在总死亡率率[RR=1.093,95%CI(0.759,1.573)]、动脉血栓事件发生率[RR=1.011,95%CI(0.673,1.520)]、中风发生率[RR=0.830,95%CI(0.390,1.766)],非致死性心肌梗死发生率[RR=0.969,95%CI(0.482,1.951)],血管源性死亡发生率[RR=1.236,95%CI(0.627,2.436)],静脉血栓事件发生率[RR=2.458,95%CI(0.986,6.131)]上均无统计学差异。结论 Meta分析结果表明Bevacizumab与Ranizumab治疗年龄相关性黄斑变性具有相似的全身安全性,但尚需更多高质量的前瞻性研究结果进一步验证和支持。
[Abstract]:Objective to evaluate the safety of intravitreal injection of bevacizumab and Ranibizumab in the treatment of age-related macular degeneration. Methods computer search was conducted for Pubmedus EMbase Cochrane Library, Chinese Biomedical Literature Database (CBMN), CNKI, Weip Database and Wanfang Database. A randomized controlled study of Bevacizumab and Ranibizumab in the treatment of age-related macular degeneration was conducted and the references were also found. The time limit for retrieval is from the construction of the database to December 1, 2013. The quality of RCT was evaluated strictly and the data was extracted, and the RCT in accordance with the quality standard was analyzed by meta-analysis. Results A total of 5 RCTs were included, with a total of 2382 eyes. The homogeneity of systemic safety indexes in all studies was good, and fixed effect model was used for meta-analysis. 缁撴灉鏄剧ず:Bevacizumab缁勪笌Ranibizumab缁勭浉姣，

本文编号：2020990